NO. | Beijing Time (UTC+8) | Local Time | Type | Presentation Topic | Speaker | |
---|---|---|---|---|---|---|
1 | 13:20-13:35 | 13:20-13:35 | Plenary Lecture |
TBD |
TB D | |
2 | 13:35-13:50 | 13:35-13:50 | Plenary Lecture |
Single cell sequencing reveals heterogeneity changes in the microenvironment of melasma |
Li He | |
3 | 13:50-14:05 | 13:50-14:05 | Plenary Lecture |
TBD |
Tong Lin | |
4 | 14:05-14:20 | 14:05-14:20 | Plenary Lecture |
Cellular senescence and pigmentation |
Kang Hee Young | |
5 | 14:20-14:35 | 14:20-14:35 | Plenary Lecture |
topic 5:Therapeutic Strategies and Latest Clinical Advances in Melasma |
Jin Chen | |
6 | 14:35-14:45 | 14:35-14:45 | Comment |
Q&A |
NO. | Beijing Time (UTC+8) | Local Time | Type | Presentation Topic | Speaker | |
---|---|---|---|---|---|---|
1 | 15:40-15:50 | 15:40-15:50 | Oral Presentation |
Ultraviolet-Induced Erythema and Pigmentation in Skin with Varying Degrees of Epidermal Permeability Barrier Damage: An Experimental Study |
Hua Gu | |
2 | 15:50-16:00 | 15:50-16:00 | Oral Presentation |
The quality of life and psychosocial burden of Riehl's melanosis in China: A cross-sectional study |
Yuecen Ding | |
3 | 16:00-16:10 | 16:00-16:10 | Oral Presentation |
Immune Mechanism of Melanophages Formation and its Clinical Significance in Riehl’s Melanosis |
Chen Wang | |
4 | 16:10-16:20 | 16:10-16:20 | Oral Presentation |
A retrospective study on the efficacy and adverse effects with the use of hydroquinone monotherapy versus combination topical agents in melasma |
Samuel Morriss | |
5 | 16:20-16:30 | 16:20-16:30 | Oral Presentation |
The therapeutic and preventive effects of light-emitting diodes (LED) irradiation for post-inflammatory erythema and hyperpigmentation: a clinical observation |
Yanjun Dan | |
6 | 16:30-16:40 | 16:30-16:40 | Oral Presentation |
Deciphering the Heterogeneity of Fibroblasts in Melasma and Their Molecular Mechanisms in Regulating Melanin Metabolism Based on Single-Cell Transcriptomics |
Xiaorong Jia | |
7 | 16:40-16:55 | 16:40-16:55 | Comment |
Q&A |